ReviewFrontiers in human neuroscience2022
Pathogenesis and research progress in leukoaraiosis.
Review in Frontiers in human neuroscience, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Leukoaraiosis severity and outcomes of endovascular thrombectomy for acute ischemic stroke: a systematic review and meta-analysis.European radiology · 2025Pooled it
- Relationship between carotid intima-media thickness and white matter hyperintensities in non-stroke adults: a systematic review.Frontiers in neuroanatomy · 2024Pooled it
- The Role of Leukoaraiosis and Microbleeds in Acute Ischemic Stroke Outcome Prediction.Journal of clinical medicine · 2026Article
- Analysis of Risk Factors for Leukoaraiosis: A Multicenter Retrospective Study.Brain and behavior · 2025Article
- Decoding Brain Development and Aging: Pioneering Insights From MRI Techniques.Investigative radiology · 2025Review
- Uncovering the new landscape of leukoaraiosis through the circular RNA-miRNA-mRNA axis.Frontiers in neurology · 2025Article
- A comparative study of risk factors in predictive models for cognitive dysfunction in patients with leukoaraiosis based on machine learning algorithms.Frontiers in neuroscience · 2025Article
- Cerebrovascular pathology mediates associations between hypoxemia during rapid eye movement sleep and medial temporal lobe structure and function in older adults.bioRxiv : the preprint server for biology · 2024Article
- Reduced GABA concentration in patients with white matter hyperintensities.Frontiers in neuroscience · 2023Article
- Higher High-Mobility Group Box-1 Levels are Associated with White Matter Lesions in Ischemic Stroke Patients.Journal of inflammation research · 2023Article
- The Clinical Utility of Leukoaraiosis as a Prognostic Indicator in Ischemic Stroke Patients.Neurology international · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Leukoaraiosis is a common imaging marker of cerebral small vessel disease. In recent years, with the continuous advances in brain imaging technology, the detection rate of leukoaraiosis is higher and its clinical subtypes are gradually gaining attention. Although leukoaraiosis has long been considered an incidental finding with no therapeutic necessity, there is now growing evidence linking it to, among other things, cognitive impairment and a high risk of death after stroke. Due to different research methods, some of the findings are inconsistent and even contradictory. Therefore, a comprehensive and in-depth study of risk factors for leukoaraiosis is of great clinical significance. In this review, we summarize the literature on leukoaraiosis in recent years with the aim of elucidating the disease in terms of various aspects (including pathogenesis, imaging features, and clinical features, etc.).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.